+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Antidepressants Global Market Report 2020-30: COVID-19 Implications and Growth

  • ID: 5017384
  • Report
  • April 2020
  • Region: Global
  • 300 pages
  • The Business Research Company
1 of 5

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Akeda Pharmaceutical
  • Allergan PLC
  • Eli Lilly and Co.
  • Forest laboratories
  • H. Lundbeck AS
  • Merck & Co. Inc.
  • MORE
Antidepressants Market Global Report 2020: COVID-19 Outlook from the publisher covers this critical market and the impact on it from the COVID-19 virus. It provides strategists, marketers and senior management with the critical information they need to assess the increasing demand for antidepressants which play a critical role in the treatment of patients with COVID-19.

Reasons to Purchase
  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Understand how the market is experiencing rapid growth due to the coronavirus and how it is likely to stabilize as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3 working days of order.
Description:

Where is the largest and fastest growing market for the antidepressants? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Antidepressants market global report from the publisher answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider antidepressants market, and compares it with other markets.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the influence of the COVID-19 virus and forecasting its growth.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
  • The antidepressants market section of the report gives context. It compares the antidepressants market with other segments of the antidepressants market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, antidepressants indicators comparison.
Scope

Markets Covered: 1) By Product: Selective Serotonin Reuptake Inhibitor (SSRI); Serotonin-norepinephrine Reuptake Inhibitor (SNRI); Tricyclic Antidepressant (TCA); Monoamine Oxidase Inhibitor (MAOI); 2) By Drug Class: Monoamine oxidase inhibitors; Serotonin antagonist and reuptake inhibitors; Serotonin-norepinephrine reuptake inhibitors; Selective serotonin reuptake inhibitors; Tricyclic antidepressants; 3) By Depressive Disorder: Major Depressive Disorder; Obsessive-Compulsive Disorder; Generalized Anxiety Disorder; Panic Disorder

Companies Mentioned: Allergan PLC; AstraZeneca; Eli Lilly and Company; GlaxoSmithKline PLC; H. Lundbeck AS

Countries: Argentina; Australia; Austria; Belgium; Brazil; Canada; Chile; China; Colombia; Czech Republic; Denmark; Egypt; Finland; France; Germany; Hong Kong; India; Indonesia; Ireland; Israel; Italy; Japan; Malaysia; Mexico; Netherlands; New Zealand; Nigeria; Norway; Peru; Philippines; Poland; Portugal; Romania; Russia; Saudi Arabia; Singapore; South Africa; South Korea; Spain; Sweden; Switzerland; Thailand; Turkey; UAE; UK; USA; Venezuela; Vietnam

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Akeda Pharmaceutical
  • Allergan PLC
  • Eli Lilly and Co.
  • Forest laboratories
  • H. Lundbeck AS
  • Merck & Co. Inc.
  • MORE
1. Executive Summary

2. Antidepressants Market Characteristics

3. Antidepressants Market Size and Growth
3.1. Global Antidepressants Historic Market, 2015 - 2019, $ Billion
3.1.1. Drivers Of The Market
3.1.2. Restraints On The Market
3.2. Global Antidepressants Forecast Market, 2019 - 2023F, 2025F, 2030F, $ Billion
3.2.1. Drivers Of The Market
3.2.2. Restraints On the Market

4. Antidepressants Market Segmentation
4.1. Global Antidepressants Market, Segmentation by Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Selective Serotonin Reuptake Inhibitor (SSRI)
  • Serotonin-norepinephrine Reuptake Inhibitor (SNRI)
  • Tricyclic Antidepressant (TCA)
  • Monoamine Oxidase Inhibitor (MAOI)
  • Other Products
4.2. Global Antidepressants Market, Segmentation by Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Monoamine oxidase inhibitors
  • Serotonin antagonist and reuptake inhibitors
  • Serotonin-norepinephrine reuptake inhibitors
  • Selective serotonin reuptake inhibitors
  • Tricyclic antidepressants
  • Others
4.3. Global Antidepressants Market, Segmentation by Depressive Disorder, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Major Depressive Disorder
  • Obsessive-Compulsive Disorder
  • Generalized Anxiety Disorder
  • Panic Disorder
  • Others
5. Antidepressants Market Regional and Country Analysis
5.1. Global Antidepressants Market, Split by Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
5.2. Global Antidepressants Market, Split by Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

6. Asia-Pacific Antidepressants Market
6.1. Asia-Pacific Antidepressants Market Overview
6.2. Asia-Pacific Antidepressants Market, Segmentation by Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

7. China Antidepressants Market
7.1. China Antidepressants Market Overview
7.2. China Antidepressants Market, Segmentation by Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F,$ Billion

8. India Antidepressants Market
8.1. India Antidepressants Market Overview
8.2. India Antidepressants Market, Segmentation by Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

9. Japan Antidepressants Market
9.1. Japan Antidepressants Market Overview
9.2. Japan Antidepressants Market, Segmentation by Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

10. Australia Antidepressants Market
10.1. Australia Antidepressants Market, Segmentation by Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

11. Indonesia Antidepressants Market
11.1. Indonesia Antidepressants Market, Segmentation by Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

12. South Korea Antidepressants Market
12.1. South Korea Antidepressants Market, Segmentation by Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

13. Western Europe Antidepressants Market
13.1. Western Europe Antidepressants Market Overview
13.2. Western Europe Antidepressants Market, Segmentation by Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

14. UK Antidepressants Market
14.1. UK Antidepressants Market Overview
14.2. UK Antidepressants Market, Segmentation by Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

15. Germany Antidepressants Market
15.1. Germany Antidepressants Market, Segmentation by Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

16. France Antidepressants Market
16.3. France Antidepressants Market, Segmentation by Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

17. Eastern Europe Antidepressants Market
17.1. Eastern Europe Antidepressants Market Overview
17.2. Eastern Europe Antidepressants Market, Segmentation by Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

18. Russia Antidepressants Market
18.1. Russia Antidepressants Market, Segmentation by Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

19. North America Antidepressants Market
19.1. North America Antidepressants Market Overview
19.2. North America Antidepressants Market, Segmentation by Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

20. USA Antidepressants Market
20.1. USA Antidepressants Market Overview
20.2. USA Antidepressants Market, Segmentation by Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

21. South America Antidepressants Market
21.1. South America Antidepressants Market Overview
21.2. South America Antidepressants Market, Segmentation by Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

22. Brazil Antidepressants Market
22.1. Brazil Antidepressants Market, Segmentation by Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

23. Middle East Antidepressants Market
23.1. Middle East Antidepressants Market Overview
23.2. Middle East Antidepressants Market, Segmentation by Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

24. Africa Antidepressants Market
24.1. Africa Antidepressants Market Overview
24.2. Africa Antidepressants Market, Segmentation by Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

25. Antidepressants Market Competitive Landscape and Company Profiles
25.1. Antidepressants Market Competitive Landscape
25.2. Antidepressants Market Company Profiles
25.2.1. Allergan PLC
25.2.1.1. Overview
25.2.1.2. Products and Services
25.2.1.3. Strategy
25.2.1.4. Financial Performance
25.2.2. AstraZeneca
25.2.2.1. Overview
25.2.2.2. Products and Services
25.2.2.3. Strategy
25.2.2.4. Financial Performance
25.2.3. Eli Lilly and Company
25.2.3.1. Overview
25.2.3.2. Products and Services
25.2.3.3. Strategy
25.2.3.4. Financial Performance
25.2.4. GlaxoSmithKline PLC
25.2.4.1. Overview
25.2.4.2. Products and Services
25.2.4.3. Strategy
25.2.4.4. Financial Performance
25.2.5. H. Lundbeck AS
25.2.5.1. Overview
25.2.5.2. Products and Services
25.2.5.3. Strategy
25.2.5.4. Financial Performance

26. Key Mergers and Acquisitions In The Antidepressants Market

27. Antidepressants Market Trends and Strategies

28. Antidepressants Market Future Outlook and Potential Analysis

29. Appendix
29.1. Abbreviations
29.2. Currencies
29.3. Research Inquiries
29.4. About the Publisher
29.5. Copyright and Disclaimer
Note: Product cover images may vary from those shown
3 of 5

FEATURED COMPANIES

  • Akeda Pharmaceutical
  • Allergan PLC
  • Eli Lilly and Co.
  • Forest laboratories
  • H. Lundbeck AS
  • Merck & Co. Inc.
  • MORE
Major players in the antidepressants market are Allergan PLC, AstraZeneca, Eli Lilly and Company, GlaxoSmithKline PLC, H. Lundbeck AS, Johnson & Johnson, Pfizer Inc., Merck & Co. Inc., Sanofi, and Sun Pharmaceuticals Pvt Ltd.

The global antidepressants market is expected to grow from $14.3 billion in 2019 to about $28.6 billion in 2020 as mental health issues are expected to surge due to the effects of the Covid-19 pandemic making an impact on the global economy. The market is expected to stabilize and reach $19 billion at a CAGR of 7.4% through 2023.

The antidepressants market has also surged during the covid-19 outbreak. The increasing number of cases and fatalities is affecting the mental health by elevating anxiety worldwide. People who are already living with mental health problems are experiencing increased stress levels over the Covid-19 outbreak. This has triggered the demand for antidepressant drugs.

The antidepressants market consists of sales of antidepressants and related services that are used in retail pharmacies, hospitals and clinics. Antidepressants are drugs that can help to alleviate depressive symptoms, social anxiety disorder, anxiety disorders, seasonal affective disorder, and dysthymia, or moderate persistent depressive, as well as other conditions. The antidepressant medications available include the antagonists of SSRIs or selective serotonin reuptake, MAOIs or monoamine oxidase inhibitors, tricyclic antidepressants, tetracyclic antidepressants and others.

The antidepressants market covered in this report is segmented by product into selective serotonin reuptake inhibitor (SSRI); serotonin-norepinephrine reuptake inhibitor (SNRI); tricyclic antidepressant (TCA); monoamine oxidase inhibitor (MAOI); other products. It is also segmented by drug class into monoamine oxidase inhibitors; serotonin antagonist and reuptake inhibitors; serotonin-norepinephrine reuptake inhibitors; selective serotonin reuptake inhibitors; tricyclic antidepressants; others and by depressive disorder into major depressive disorder; obsessive-compulsive disorder; generalized anxiety disorder; panic disorder; others.

In May 2018, Allergan, an Ireland based company, focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world acquired Aptinyx for an unclosed amount. Through this acquisition Allergan gained important insights into NMDA receptor modulation as a potential therapeutic approach for depression. Aptinyx, a clinical-stage biopharmaceutical company focused on the discovery and development of transformative therapies for challenging neurologic disorders.

The side-effects and patent expiry of antidepressant drugs is a key factor hampering the growth of the antidepressant market. The antidepressants are Lexapro (escitalopram) and Celexa (citalopram), both of which are used to treat depression, Lexapro also helps for anxiety. Lexapro and Celexa can cause side effects common to others which includes nausea, sleeplessness, sweating, dry mouth and drowsiness. Celexa and Lexapro are both at risk for even more serious side effects including excessive bleeding, seizures and vision issues. In 2018 the labels of the medications contained a black box warning for an increased suicide risk. Therefore, the side-effects and patent expiry of antidepressant drugs is expected to limit the growth of the antidepressant market.

The treatment for resistant depression is a key trend in the antidepressant market. Ketamine is the new treatment that is used for anesthesia during surgery, stimulates the development of glutamate, and prompts the brain to form new neural connections. It makes the brain more adaptable and capable of developing new pathways and helps people to create more optimistic thoughts and behaviours. In 2018, Food and Drug Administration (FDA) approved ketamine, an anesthetic that has made waves for its surprising antidepressant effect. Since treatment with esketamine may be of great benefit to patients with treatment-resistant depression (meaning conventional therapies have not benefited them), the FDA has speeded up the approval process to make it available more rapidly.

Globally, rising cases of mental health disorders are the key factor in the growth of the antidepressant drug industry, as many customers rely on these medications to counter depression, anxiety disorder etc. Antidepressant medications are used in conditions such as depression, OCD, childhood enuresis, major depressive disorder, severe anxiety disorder, bipolar disorder, post-traumatic stress disorder (PTSD), social anxiety disorder, etc. Globally, the percentage of people with depression varies from 2% to 6% and the elderly are at greater risk of depression relative to other age groups. According to WHO, in 2020, about 264 million people of all ages worldwide suffer from depression. Therefore, rising cases of mental health disorders is expected to drive the growth of the antidepressant market.
Note: Product cover images may vary from those shown
4 of 5
  • Allergan PLC
  • AstraZeneca
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • H. Lundbeck AS
  • Johnson & Johnson
  • Pfizer Inc.
  • Merck & Co. Inc.
  • Sanofi
  • Sun Pharmaceuticals Pvt Ltd
  • Alkermes
  • Bristol Myers Squibb Company
  • Teva Pharmaceutical Industries
  • Eli Lilly and Co.
  • Takeda Pharmaceutical Co. Ltd
  • Forest laboratories
  • Akeda Pharmaceutical
  • Others
Note: Product cover images may vary from those shown
5 of 5

Loading
LOADING...

Adroll
adroll